From isolated GH deficiency to multiple pituitary hormone deficiency: an evolving continuum - a KIMS analysis

Area of Science:

• Endocrinology
• Metabolic Disorders
• Clinical Research

Background:

• Adult-onset growth hormone deficiency (AO-GHD) encompasses isolated GH deficiency (IGHD) and multiple pituitary hormone deficiency (MPHD).
• Understanding the natural history and treatment response in these conditions is crucial for effective patient management.

Purpose of the Study:

• To compare the clinical presentation, GH therapy effects, and progression of AO-IGHD to MPHD.
• To identify factors influencing the development of new pituitary hormone deficiencies.

Main Methods:

• An observational prospective study analyzed data from 4110 patients in the Pfizer International Metabolic Database (KIMS).
• Baseline characteristics, 2-year GH replacement effects, and new deficiency development were assessed in IGHD and MPHD cohorts.

Main Results:

• IGHD and MPHD patients showed similar baseline presentations and responded comparably to 2 years of GH therapy, with improvements in lipid profiles and quality of life.
• New deficiencies developed in 35% of IGHD patients, similar to MPHD patients, often within the first year but observed up to 6 years post-treatment initiation.
• Conversion to MPHD was not predicted by initial factors, while age and disease duration predicted additional deficits in MPHD patients.

Conclusions:

• Adult-onset IGHD and MPHD share similar clinical presentations and GH therapy responses.
• Hypopituitarism is a dynamic condition, with new deficiencies appearing years after diagnosis, underscoring the need for vigilant endocrine follow-up in all hypopituitary patients.